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Tetrahydrofuranosyl-1,2,3-triazoles, synthesized by “Click chemistry”, were tested as novel antifungal compounds. The 
results show a remarkable activity against Candida albicans ATCC 10231 expressed in a high MIC50 and MIC90 compared to 
traditional antifungals such as fluconazole. 
 




Copper-Catalyzed Alkyne-Azide Cycloaddition (CuAAC) is the best known example of an ideal reaction for 
“Click Chemistry”, which is a modular approach to attach distinct molecules in order to enhance diverse properties 
and to increase the applications for different purposes, in particular, in materials science and medicinal chemistry 
[1,2]. “Click chemistry” is a synthetic chemistry subarea based on the optimization of small materials and simple 
reactions [3-5], which has already proven to be a powerful tool in the preparation of ideal "building blocks" involving 
heteroatoms [6,7] and including simple reaction conditions in presence of oxygen, water, materials, reagents 
affording a simple product isolation. These conditions are fully provided by CuAAC that is reliable for different types 
of components and functional groups [5].  
On the other hand, invasive fungal infections in immunocompromised patients have increased in recent years [8], 
with several variables contributing to this problem; fundamentally those affected with AIDS, patients undergoing 
cancer chemotherapy and treated with steroids [9]. Furthermore, the emerging in vitro intrinsic fungal resistance 
against classic antimycotics is an important factor in the HIV-infected patients with Candida albicans [10]. In 
addition, the widespread use of classic antimycotics such as fluconazole in the treatment and prevention of Yeast 
infections has put in evidence the detection of decreased susceptibility to this drug [11]. The number of available 
antifungal agents for systemic use is rather limited [12] and synergistic actions have been explored [13]. In this 
concern, a new kind of antifungals with 1,2,3-triazole moiety [2] may be an improvement for clinical options in 
parallel with less toxicity. 
The triazole antifungal agents belong to the Sterol Biosynthesis Inhibitors (SBI's); a class of fungicides widely 
used to treat mycotic diseases in humans and animals. The molecular spatial conformation of the fungicide is a 
crucial factor which can increase or reduce the activity of the molecule. Conventional triazoles as fluconazole have 
decreased effectiveness indices in these infections.  
The elements above-mentioned motivated us to initiate an extensive investigation in order to explore the 
possibility to use 1,2,3-triazoles as novel antifungals. The aim of this study was to evaluate the susceptibility of 
Candida albicans ATCC 10231 to tetrahydrofuranosyl-1, 2, 3-triazoles obtained via “Click chemistry”. 
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RESULTS AND DISCUSSION 
 
Comparing the results with the Yeast microdilution method, triazol C showed statistical significant difference 
with triazol A (p = 0.007), triazol B (p = 0.008) and triazol D (p = 0.007), while, with the microdilution method 
triazol C showed statistical significant differences with triazol A (p = 0.005), triazol B (p = 0.005) and triazol D (p = 
0.005) (Table 1). 
 
Table 1. In vitro susceptibly Candida albicans ATCC 10231 to tetrahydrofuranosyl-1, 2, 3-triazoles obtained via “click 
chemistry” (Sensititre vs Yeast microdilution method) 
  MIC range (µg/ml)  
Candida 





Fluconazole 0.125 - 256 0.125 - 256 
Triazole A 1-4 1-4 
Triazole B 1-32 1-32 




Triazole D 1-4 1-32 
≤ 0.01* † 
*: with the Yeast microdilution method between triazol C and triazol A, triazol B and triazol D (p = 0.007). †: with the microdilution method between triazol C and triazol 
A, triazol B and triazol D. 
 
The MIC determination by the microdilution method used in this study, allowed us to comparatively determine 
the effectiveness of triazoles versus fluconazole. In this respect, the studied Candida strain showed decreased 
susceptibility to fluconazole (range 0.125-256 µg/ml), in contrast, the triazoles, synthesized via “Click chemistry” 
showed a tendency for a better effectiveness in terms of MIC than fluconazole (used as an internal control), although 
we did not reach significant statistical difference due to the number of samples. Being more specific, triazoles A and 
D showed, in vitro, an important index of effectiveness to inhibit the growth of Candida albicans.  
It is recognized that the percentages of Candida albicans resistance to fluconazole have increased in the past decade, 
reducing the chances of effective treatment in patients affected by this agent [14]. It is, therefore, imperative to 
develop new antifungal drugs with higher levels of effectiveness than the actual antimycotics, in order to cut the death 
rates in immunocompromised patients.  
Overall, antifungal susceptibility testing results of clinically significant Candida species are of interest for 
empiric and prophylactic therapies. In fact, in vitro antifungal susceptibility testing is now standardized 
internationally [15] and is becoming essential in patient management and resistance surveillance [16]. 
Several studies have compared the antifungal susceptibility profiles of fluconazol and other antimycotics [17,18] but 
until now the experience with triazoles via “Click Chemistry” is scarce and in vitro [19,20]. With the CuAAC 
technique we are reaching the required functionality to potentiate the biological activities of new compounds. Copper 
complexes derived from the propenditioic acid are stable to the environmental conditions of temperature and 
humidity showing an excellent catalytic activity in the azide-alkyne cycloadditions as the binder of the catalyst 
stabilizes the oxidation state of copper, making unnecessary, in principle, adding a reducing agent or an organic base 
to stabilize the transition metal [21].  
Much attention has been focused on the antimicrobial [22] and antiparasitic [23] actions of triazoles. In our study 
we used the synthesis of novel 1,2,3-triazoles containing rings of five members with or without oxygen as 
substituents, in order to prepare in a simple way compounds which mimic nucleotides with possible antimycotic 
activity.  
A deeper study of the compounds tested here is required to verify their clinical effect in order to corroborate 
their pharmacological perspective use since “Click Chemistry” synthesis offers great expectations for the 
development of new effective antifungal agents. 
 
EXPERIMENTAL 
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The four tested triazoles, were provided by Dr. Erick Cuevas-Yañez, from CIQS, UAEM-UNAM (Table 2 and 
Figures 1 and 2), and they were synthesized using CuAAC according to previous reports [2,24].  
 
Table 2. 1, 2, 3-triazoles synthesis (modified from Velasco, B.; et al [2]) 
Found Triazole 
C H N 
4-{1-[5-Chloro-2-(2,4-dichloro-phenoxy)-phenyl]-1,2,3-triazol-4-ylmethoxy}-benzoic acid 
methyl ester (28).  
White solid, m.p. 157 °C. IR (ATR, cm-1): 1700, 1600, 1350, 1260. 1H NMR (500 MHz, CDCl3): δ 
3.78 (s, 3H), 5.30 (s, 2H), 7.02 (d, 1H, J=9 Hz), 7.13 (m, 2H), 7.22 (d, 1H, J=9 Hz), 7.41 (d, 1H, 
J=2.5Hz), 7.56 (d, 1H, J=2.5 Hz), 7.70 (d, 1H, J=2.5 Hz), 7.86 (m, 2H), 7.94 (d, 1H, J= 2.5 Hz), 8.68 
(s, 1H). 13 C NMR (125 MHz, CDCl3): δ 52.2, 61.3, 115.2, 120.1, 122.673, 123.0, 126.1, 126.7, 
127.0, 128.3, 128.5, 129.4, 130.2, 130.7, 131.3, 131.6, 142.9, 147.8, 149.7, 162.1, 166.2. MS [EI+] 
m/z(%): 418 (23), 324 (64), 288 (100), 290 (80), 254 (70), 161 (54). HRMS (EI+): for 
C23H16Cl3N3O4 calcd. 503.0206, found 503.0209. Anal. Calcd for C23H16Cl3N3O4: C, 54.73%; H, 
3.20%; N, 8.32%. 
54.62% 3.29% 8.37% 
4-[5-Chloro-2-(2,4-dichlorophenoxy)-phenoxymethyl]-1-(4-chloro-phenyl)-1H-[1,2,3]triazole 
(21).  
White solid, m.p. 160.0 °C. IR (ATR, cm-1): 3100, 1550, 1500, 1250. 1H NMR (500 MHz, CDCl3): 
δ 5.27 (s, 2H), 6.67 (d, 1H, J=9Hz), 6.95 – 6.99 (m, 1H), 7.09 - 7.11 (d, 1H, J=3Hz), 7.18 – 7.19 (d, 
1H, J=3Hz), 7.26 (s, 1H), 7.41 – 7.442(d, 1H, J=3Hz), 7.51 – 7.52 (d, 1H, J=3Hz), 7.63 - 765 (m, 
1H), 7.67 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 63.6, 115.966, 118.2, 120.4, 121.5, 122.1, 122.3, 
124.4, 127.8, 128.1, 130.0, 130.1, 130.7, 134.7, 135.3, 143.3, 144.5, 149.8, 152.3. MS [EI+] m/z(%): 
479 [M]+ (5), 318 (8), 290 (17), 164 (100), 128 (27), 111 (41). HRMS (EI+): for C21H13Cl4N3O2 
calcd. 478.9762, found 478.9764. Anal. Calcd for C21H13Cl4N3O: C, 54.22%; H, 2.82%; N, 9.03%.  
54.87% 2.89% 9.12% 
4-[5-Chloro-2-(2,4-dichlorophenoxy)-phenoxymethyl]-1-(3,4-dichloro-phenyl)-1,2,3-triazole  
White solid, m.p. 163 °C. IR (ATR, cm-1): 3100, 1550, 1500, 1250, 1000. 1H NMR (500 MHz, 
CDCl3): δ 5.17 (s, 2H), 5.56 (s, 2H), 6.69 (d, 1H, J=9Hz), 7.023 (s, 2H), 7.20 – 7.25 (m, 3H), 7.33 - 
7.35 (m, 3H), 7.47 – 7.47 (m, 1H,), 7.54 – 7.55 (m, 1H), 7.95 (s, 1H). 13C NMR (125 MHz, CDCl3): 
δ 53.3, 62.7, 116.1, 119.1, 121.9, 122.4, 123.8, 124.9, 127.5, 128.3, 128.6, 128.7, 129.2, 129.9, 
130.1, 136.2, 142.8, 143.1, 150.3, 152.1. MS [EI+] m/z(%): 513 [M]+ (15), 145 (100). HRMS (EI+): 
for C21H12Cl5N3O2 calcd. 512.9372, found 512.9375. 





















Figure 1: Model of tetrahydrofuranosyl-1, 2, 3-triazoles synthesis (modified from Velasco, B.; et al [2]) 
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Figure 2: Tetrahydrofuranosyl-1, 2, 3-triazoles synthesized via “click chemistry” by reactivity of azides and alkynes front various 
copper salts and complexes (I). A. 4-{1-[5-Chloro-2-(2,4-dichloro-phenoxy)-phenyl]-1,2,3-triazol-4-ylmethoxy}-benzoic acid 
methyl Ester. B 4-[5-Chloro-2-(2,4-dichlorophenoxy)-phenoxymethyl]-1-(4-chloro-phenyl)-1H-[1,2,3]triazole (21). C. 4-[5-
Chloro-2-(2, 4-dichlorophenoxy)-phenoxymethyl]-1-(3,4-dichloro-phenyl)-1,2,3-triazole. D.4-[3-Chloro-2-(2,4-
dichlorophenoxy)]-1,2,3-triazole (modified from Velasco, B.; et al [2]) 
 
The starting materials were used without further purification and the solvents were distilled before use. Silica 
plates of 0.20 mm thickness were used for thin layer chromatography. Melting points were determined with a Fisher-
Johns melting point apparatus and they are uncorrected. 1H and 13C NMR spectra were recorded using a Varian 500. 
The chemical shifts (δ) are given in ppm relative to TMS as internal standard (0.00). For analytical purposes the mass 
spectra were recorded on a Shimadzu GCMS-QP2010 Plus in the EI mode, 70 eV, 200 °C via direct inlet probe. Only 
the molecular and parent ions (m/z) are reported. IR spectra were recorded on a Bruker Tensor 27 equipment. 
 
Synthesis of 1,2,3-triazoles 
 
The appropriate alkyne (1.05 mol) was added in one portion to a solution of the corresponding azide (1 mol) and 
the catalyst (3-Hydroxy-3-phenyl-2-propenedithioate-S,S’)bis(triphenylphosphine-P)copper(I) (0.005 mmol) in 
acetonitrile (30 mL) [2,24]. The resulting mixture was stirred at 60° C for 2 h or at room temperature for 10 h. The 
mixture was cooled to room temperature and the solvent was removed in vacuo. The reaction product was extracted 
with toluene (40 ml) and treated with activated charcoal (0.5 g). The mixture was filtered and evaporated under 
vacuum, and the product was crystallized from hot ethyl acetate and n-heptane. 
 
Yeast microdilution method 
 
Tetrahydrofuranosyl-1, 2, 3-triazoles, synthesized by “Click chemistry”, were probed in RPMI agar (Sigma 
Aldrich, St Louis MO, USA) with Candida albicans ATCC 10231, following the next steps:  
a. Solution preparation: it was done weighing sufficient powder to obtain a concentration at least 100 times the 
highest concentration of the antifungal drug tested [25]. 
b. Fluconazole (Pfizer, Mexico) (concentration of 2 mg/ml). The diluent used was sterile distilled water. For 
preparation of fluconazole dilutions we followed the method of additive double serial dilutions. The prepared 
dilutions differed according to whether being soluble or not in water [26]. Dilution of fluconazole (soluble in water) 
was prepared at a dilution series concentration 10 times higher than the desired final concentration, using RPMI 1640 
(Sigma Aldrich, St Louis MO, USA) as diluent. Subsequently a 1/5 dilution was added to all tubes (4 ml of RPMI), 
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so that the antifungal concentration was twice the desired final concentration (128 µg/ml to 0.25 µg/ml). The final 
concentration obtained in the plate after inoculation was between 64 and 0.12 µg/ml. 
c. Triazoles dilution (insoluble in water): From the stock solution, dilution series concentration 100 times the 
desired final concentration was prepared, using DMSO (Sigma Aldrich, St Louis MO, USA) as diluent. Each tube 
was transferred to another tube with RPMI (4.9 ml), whereupon the antifungal obtained concentration was twice the 
desired final concentration (32 µg/ml - 0.06 µg/ml) and 2% DMSO. 
d. Filling plates: 100 µl per well in column two were taken from tube two and so on to column No. 11; wells in 
column No. 12 were filled, in the case of the fluconazole dilution, with 100 µl of RPMI (growth control) and in the 
case of triazoles dilution with 100 µl of the dilution resulting from 4.9 ml of RPMI and 100 µl of 2% DMSO. Wells 
in column No. 1 were filled with 200 µl of RPMI (sterile control). Once filled, plates were closed and frozen at -70°C 
until use. 
e. Inoculum preparation: before preparing the inoculum we sowed with Saboraud Dextrose Agar (SDA) (Sigma 
Aldrich, St Louis MO, USA) for 24 hours at 30°C. In the case of Candida spp strains used in our study, the inoculum 
was prepared taking a sterile loop of culture (about five colonies ≥ 1 mm) after 24 hours of growth on SDA. 
f. A plate was suspended in a tube with sterile distilled water. Stirring well it was adjusted to an optical density of 
0.5 McFarland. The addition of the required amount of sterile distilled water was done with the aid of a 
spectrophotometer (wavelength at 530 nm). 
g. Inoculation: plates were taken from the freezer and left at room temperature until completely thawed. 
h. Incubation: plates were incubated at 35°C for 48 hours [27]. 
i. Reading and interpreting the results: Visual readout was performed using an inverted mirror. For azoles, such 
as fluconazole and triazoles, the minimum inhibitory concentration (MIC) was defined as the lowest antifungal 
concentration that produced a ≥ 50% reduction of yeast growth as compared with the drug free control growth [28]. 
 
Sensititre yeast one method 
 
This system is based on a technique of RPMI 1640 glucose broth microdilution. It contains an indicator of redox 
growth, which detects pH variations (Alamar blue), allowing the determination of in vitro sensitivity, and by 
colorimetric changes also quantifies different triazoles, including fluconazole. The steps were the next:  
a. With the help of a sterile loop, we took in SDA five colonies less than 1 mm, and evaluated the growth of 
Candida albicans ATCC 10231 after 24 hours. 
b. Emulsify the colonies in a tube of distilled water, after stirring we adjusted a spectrophotometer (wavelength 
530 nm) to an optical density of 0.5 on the McFarland scale (1-5 × 106 Colony Forming Units (CFUs)/ml). 
c. Inoculate 20 ml of this suspension in the 10 ml tube of culture medium (working dilution: 1.5 to 8 × 103 
CFU/ml). 
d. The panel was rehydrated by dispensing 100 µl of the inoculum suspension in each well. 
e. The plates, previously sealed with self-adhesive paper, were aerobically incubated at 35°C for 24-48 hours for 
Candida albicans ATCC 10231. After this period of time, we counted the number of CFUs, registering between 15 
and 18 colonies. 
For validation of results, a control shift (pink) growth was first checked. The interpretation of the results and the 
MIC calculation were determined after 24 hours of incubation. The MIC was the lowest antifungal concentration 
showing no color change (the first blue well). However, in the azoles it may appear an intermediate purple color (due 
to trailing effects) (Figure 3); in this case MIC was the concentration of the first purple well. For those genera and 
species with more than five tested strains, MIC50 and MIC90 were calculated. 
Statistical analysis was performed using SPSS version 19. We estimated the differences between the study 
groups by Mann Whitney U test. A p ≤ 0.05 was considered significant. 
 
CONCLUSIONS 
The antimycotic activity determination of 1,2,3-triazoles compounds synthesized from CuAAC represents 
significant importance in the continuing development of new pharmacological alternatives to treat diseases of 
multiple etiologies. The antifungal resistance indices have presented an exponential behavior especially in yeast 
causing opportunistic infections in patients with immunosuppressant status. The Yeast microdilution is an effective 
method to semiquantitatively measure the effectiveness indexes of triazoles calculation based on the MIC50 and 
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MIC90 for Candida albicans ATCC 10231. This strain showed high sensitivity to antifungal agents A, C and D and 
poor sensitivity to antifungal agent B. Therefore, the effective compounds must be used in other studies for 
determining susceptibility and clinical viability in inhibiting fungal growth in hospital strains isolates where such 
microorganisms are causing severe infections. 
The proposed advantages by the synthesis of pharmacologically active compounds through “Click chemistry” is 
cost-effective in the development of new drug therapies that might contribute to reduce the actual resistance rising 
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